Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a randomized clinical trial
Jay C Horrow, Wen Li, Manfred Blobner, John Lombard, Marcel Speek, Matthew DeAngelis, W Joseph Herring, Jay C Horrow, Wen Li, Manfred Blobner, John Lombard, Marcel Speek, Matthew DeAngelis, W Joseph Herring
Abstract
Background: This randomized, double-blind trial evaluated sugammadex-mediated recovery time from rocuronium- or vecuronium-induced moderate (M-) or deep (D-) neuromuscular block in morbidly obese adults dosed by actual (ABW) or ideal body weight (IBW).
Methods: Adults with BMI ≥40 kg/m2 were randomized to 1 of 5 groups: M-neuromuscular block, sugammadex 2 mg/kg ABW; M-neuromuscular block, sugammadex 2 mg/kg IBW; M-neuromuscular block, neostigmine 5 mg, and glycopyrrolate 1 mg; D-neuromuscular block, sugammadex 4 mg/kg ABW; or D-neuromuscular block, sugammadex 4 mg/kg IBW. Supramaximal train of four (TOF) stimulation of the ulnar nerve (TOF-watch SX®) monitored recovery. Primary endpoint was time to TOF ratio ≥ 0.9 for ABW and IBW groups pooled across neuromuscular blocking agent (NMBA)/blocking depth, analyzed by log-rank test stratified for agent and depth. Prespecified safety outcomes included treatment-emergent bradycardia, tachycardia, and other arrhythmias, and adjudicated hypersensitivity and anaphylaxis.
Results: Of 207 patients randomized, 188 received treatment (28% male, BMI 47 ± 5.1 kg/m2, age 48 ± 13 years). Recovery was 1.5 min faster with ABW vs IBW dosing. The sugammadex 2 mg/kg groups recovered 9-fold faster [time 0.11-fold, 95% CI 0.08 to 0.14] than the neostigmine group. ABW (5.3%) and IBW (2.7%) groups had similar incidences of recovery time > 10 min (95% CI of difference: - 4.8 to 11.0%); 84% for neostigmine group. Re-curarization occurred in one patient each in the 2 mg/kg IBW and neostigmine groups. Prespecified safety outcomes occurred with similar incidences.
Conclusions: ABW-based sugammadex dosing yields faster reversal without re-curarization, supporting ABW-based sugammadex dosing in the morbidly obese, irrespective of the depth of neuromuscular block or NMBA used.
Trial registration: Registered on November 17, 2017, at ClinicalTrials.gov under number NCT03346070 .
Keywords: Bradycardia; Multicenter trial; Neostigmine; Recurarization.
Conflict of interest statement
JCH is a former employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. WL, JL, MS, MD, and WJH are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. MB received grants and personal fees from MSD, Haar, Germany, personal fees from Grünenthal, Aachen, Germany, and personal fees from GE Healthcare, Helsinki, Finland. JCH is currently Clinical Professor of Anesthesiology & Critical Care Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Figures
References
- Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000;39:215–231. doi: 10.2165/00003088-200039030-00004.
- Forbes GB, Welle SL. Lean body mass in obesity. Int J Obes. 1983;7:99–107.
- Collis T, Devereux RB, Roman MJ, et al. Relations of stroke volume and cardiac output to body composition: the strong heart study. Circulation. 2001;103:820–825. doi: 10.1161/01.CIR.103.6.820.
- Stokholm KH, Brochner-Mortensen J, Hoilund-Carlsen PF. Increased glomerular filtration rate and adrenocortical function in obese women. Int J Obes. 1980;4:57–63.
- Ingrande J, Lemmens HJ. Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth. 2010;105(Suppl 1):i16–i23. doi: 10.1093/bja/aeq312.
- Eriksson LI, Lennmarken C, Wyon N, Johnson A. Attenuated ventilatory response to hypoxaemia at vecuronium-induced partial neuromuscular block. Acta Anaesthesiol Scand. 1992;36:710–715. doi: 10.1111/j.1399-6576.1992.tb03550.x.
- Eriksson LI, Sato M, Severinghaus JW. Effect of a vecuronium-induced partial neuromuscular block on hypoxic ventilatory response. Anesthesiology. 1993;78:693–699. doi: 10.1097/00000542-199304000-00012.
- Sundman E, Witt H, Olsson R, Ekberg O, Kuylenstierna R, Eriksson LI. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology. 2000;92:977–984. doi: 10.1097/00000542-200004000-00014.
- Kammerer MR, Porter MM, Beekley AC, Tichansky DS. Ideal body weight calculation in the bariatric surgical population. J Gastrointest Surg. 2015;19:1758–1762. doi: 10.1007/s11605-015-2910-4.
- Fresenius Kabi USA, LLC. Neostigmine Methylsulfate [package insert]. U.S. Food & Drug Administration Website. Revised January 2015. Accessed February 2, 2021.
- Blobner M, Eriksson LI, Scholz J, Motsch J, Della Rocca G, Prins ME. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anaesthesiol. 2010;27:874–881. doi: 10.1097/EJA.0b013e32833d56b7.
- Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora-Tamayo JI, Rietbergen H, Alvarez-Gomez JA. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth Analg. 2010;110:64–73. doi: 10.1213/ane.0b013e3181ac53c3.
- Herring WJ, Woo T, Assaid CA, et al. Sugammadex efficacy for reversal or rocuronium- and vecuronium-induced neuromuscular blockade: a pooled analysis of 26 studies. J Clin Anesth. 2017;41:84–91. doi: 10.1016/j.jclinane.2017.06.006.
- Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand. 2007;51:789–808. doi: 10.1111/j.1399-6576.2007.01352.x.
- Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–226. doi: 10.1002/sim.4780040211.
- Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology. 2008;109:816–824. doi: 10.1097/ALN.0b013e31818a3fee.
- Lemmens HJ, El-Orbany MI, Berry J, Morte JB, Jr, Martin G. Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: sugammadex versus neostigmine. BMC Anesthesiol. 2010;10:15. doi: 10.1186/1471-2253-10-15.
- Mulier JP, Dillemans B. Anaesthetic factors affecting outcomes after bariatric surgery, a retrospective Levelled regression analysis. Obes Surg. 2019;29:1841–1850. doi: 10.1007/s11695-019-03763-1.
- Badaoui R, Cabaret A, Alami Y, et al. Reversal of neuromuscular blockade by sugammadex in laparoscopic bariatric surgery: in support of dose reduction. Anaesth Crit Care Pain Med. 2016;35:25–29. doi: 10.1016/j.accpm.2015.09.003.
- Baete S, Vercruysse G, Vander Laenen M, et al. The effect of deep versus moderate neuromuscular block on surgical conditions and postoperative respiratory function in bariatric laparoscopic surgery: a randomized, double blind clinical trial. Anesth Analg. 2017;124:1469–1475. doi: 10.1213/ANE.0000000000001801.
- Llaurado S, Sabate A, Ferreres E, Camprubi I, Cabrera A. Sugammadex ideal body weight dose adjusted by level of neuromuscular blockade in laparoscopic bariatric surgery. Anesthesiology. 2012;117:93–98. doi: 10.1097/ALN.0b013e3182580409.
- Blobner M, Hunter JM, Meistelman C, et al. Use of a train-of-four ratio of 0.95 versus 0.9 for tracheal extubation: an exploratory analysis of POPULAR data. Br J Anaesth. 2020;124:63–72. doi: 10.1016/j.bja.2019.08.023.
- World Health Organization (WHO). The third WHO global patient safety challenge: Medication Without Harm, 2021. Accessed 04 February 2021.
- European Medicines Agency (EMA). Tackling medication errors: European Medicines Agency workshop calls for coordinated EU . [Press release]. 01 March 2013. . Accessed 04 February 2021.
- Liang SS, Stewart PA, Phillips S. An ipsilateral comparison of acceleromyography and electromyography during recovery from nondepolarizing neuromuscular block under general anesthesia in humans. Anesth Analg. 2013;117:373–379. doi: 10.1213/ANE.0b013e3182937fc4.
- Suzuki T, Fukano N, Kitajima O, Saeki S, Ogawa S. Normalization of acceleromyographic train-of-four ratio by baseline value for detecting residual neuromuscular block. Br J Anaesth. 2006;96:44–47. doi: 10.1093/bja/aei273.
Source: PubMed